文献速递新生儿儿童血液肿瘤与免疫

遗传性易栓症对新生儿血栓栓塞的临床影响:日本全国性研究

Clinical Impact of Heritable Thrombophilia on Neonatal-Onset Thromboembolism: A Nationwide Study in Japan.
PubMed 文献 · J Pediatr · 2021-07-08

本研究通过日本围产中心问卷调查2014至2018年出生28天内发生血栓栓塞的患儿,估计新生儿血栓栓塞发病率为0.39/万活产。蛋白C变异与紫癜暴发、眼出血、家族史及死亡或残疾相关,且蛋白C变异独立与残疾相关(OR 5.74, 95%CI 1.16-28.4, P=.03),但非死亡。

要点

  • 蛋白C变异患儿紫癜暴发、眼出血、家族史及死亡或残疾更常见。
  • 蛋白C变异独立与残疾相关(OR 5.74, 95%CI 1.16-28.4, P=.03),但与死亡无关。

核心结论

  • 单等位基因蛋白C变异比双等位基因变异有更高的新生儿血栓栓塞发生率。
  • 蛋白C变异独立与残疾相关(OR 5.74, 95%CI 1.16-28.4, P=.03),但与死亡无关。

研究设计与样本

  • 日本全国性问卷调查研究,针对围产中心2014至2018年出生28天内发生血栓栓塞的患者。
  • 共纳入77例新生儿血栓栓塞患者,估计发病率为0.39/万活产。

主要发现

  • 4例(5.2%)死亡,14例(18.2%)存活伴残疾。
  • 诊断时蛋白C活性<20%者16例,蛋白S活性<20%者2例,抗凝血酶活性<20%者1例。
  • 蛋白C变异患儿紫癜暴发(P<.01)、眼出血(P<.01)、阳性家族史(P=.01)及死亡或残疾(P=.03)更频繁。

关键数值与推荐

  • 蛋白C变异与残疾独立相关(OR 5.74, 95%CI 1.16-28.4, P=.03),与死亡无独立关联。
  • 4个双等位基因变异者出现严重血栓并发症如神经残疾、失明和/或截肢;3个单等位基因变异者存活无并发症。
  • 唯一的蛋白C变异死亡者为极早产杂合子婴儿。

临床怎么用

  • 新生儿血栓栓塞伴蛋白C活性低时应进行易栓症基因检测以明确遗传缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To clarify the incidence and genetic risk of neonatal-thromboembolism, we conducted a nationwide study exploring the impact of thrombophilia on neonatal-thromboembolism in Japan. STUDY DESIGN: A questionnaire survey was conducted for perinatal centers in Japan, focusing on the clinical expression, genotype, treatment, and outcome of patients who developed thromboembolism within 28 days of birth from 2014 to 2018. RESULTS: The estimated incidence of neonatal-thromboembolism was 0.39 cases per 10 000 live births. Intracranial lesions and purpura fulminans occurred in 66 and 5 of 77 patients, respectively. Fifty-eight (75.3%) infants presented within 3 days after birth. Four (5.2%) died, and 14 (18.2%) survived with disability. At the diagnosis, <20% plasma activity of protein C was noted in 16 infants, protein S (in 2), and antithrombin (in 1). Thirteen genetic tests identified 4 biallelic and 5 monoallelic protein C-variants but no protein S- or antithrombin-variants. Protein C-variants had purpura fulminans (P < .01), ocular bleeding (P < .01), positive-family history (P = .01), and death or disability (P = .03) more frequently than others. Protein C-variants were independently associated with disability (OR 5.74, 95% CI 1.16-28.4, P = .03) but not death. Four biallelic variants had serious thrombotic complications of neurologic disability, blindness, and/or amputation. Three monoallelic variants survived without complications. The only protein C-variant death was an extremely preterm heterozygote infant. CONCLUSIONS: Monoallelic protein C-variants had a higher incidence of neonatal-thromboembolism than biallelic variants. Thrombophilia genetic testing should be performed in the setting of neonatal-thromboembolism and low protein C to identify the underlying genetic defect.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Egami N, Ochiai M, Ichiyama M, et al. Clinical Impact of Heritable Thrombophilia on Neonatal-Onset Thromboembolism: A Nationwide Study in Japan. J Pediatr. 2021. PMID: 34245770. doi:10.1016/j.jpeds.2021.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。